Shared Decision-Making in the Treatment of Multiple Sclerosis: Results of a Cross-Sectional, Real-World Survey in Europe and the United States

References

• Battaglia MA, Bezzini D, Cecchini I, et al. Patients with multiple sclerosis: a burden and cost of illness study. J Neurol. 2022;269(9):5127–5135. doi:10.1007/s00415-022-11169-w
   PubMed Web of Science ®Google Scholar
• Kremer IEH, Jongen PJ, Evers S, Hoogervorst ELJ, Verhagen WIM, Hiligsmann M. Patient decision aid based on multi-criteria decision analysis for disease-modifying drugs for multiple sclerosis: prototype development. BMC Med Inform Decis Mak. 2021;21(1):123. doi:10.1186/s12911-021-01479-w
   PubMed Web of Science ®Google Scholar
• Stenager E. A global perspective on the burden of multiple sclerosis. Lancet Neurol. 2019;18(3):227–228. doi:10.1016/s1474-4422(18)30498-8
   PubMed Web of Science ®Google Scholar
• Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–1821. doi:10.1177/1352458520970841
   PubMed Web of Science ®Google Scholar
• Pérez de Heredia-Torres M, Huertas-Hoyas E, Sánchez-Camarero C, et al. Occupational performance in multiple sclerosis and its relationship with quality of life and fatigue. Eur J Phys Rehabil Med. 2020;56(2):148–154. doi:10.23736/s1973-9087.20.05914-6
   PubMed Web of Science ®Google Scholar
• Van Wijmeersch B, Hartung HP, Vermersch P, et al. Using personalized prognosis in the treatment of relapsing multiple sclerosis: a practical guide. Front Immunol. 2022;13:991291. doi:10.3389/fimmu.2022.991291
   PubMed Web of Science ®Google Scholar
• Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15(5):287–300. doi:10.1038/s41582-019-0170-8
   PubMed Web of Science ®Google Scholar
• Araujo L, Geertsen SS, Amedume A, Higuchi K, van Wingerden J. Persistence; adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world study. Neurol Ther. 2022;11(4):1735–1748. doi:10.1007/s40120-022-00404-1
   PubMed Web of Science ®Google Scholar
• Samjoo IA, Worthington E, Drudge C, et al. Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res. 2021;10(6):495–507. doi:10.2217/cer-2020-0267
   PubMed Web of Science ®Google Scholar
• Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic advances in multiple sclerosis. Front Neurol. 2022;13:824926. doi:10.3389/fneur.2022.824926
   PubMed Web of Science ®Google Scholar
• Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. Mult Scler. 2017;23(2):185–190. doi:10.1177/1352458516671204
   PubMed Web of Science ®Google Scholar
• Cofield SS, Thomas N, Tyry T, Fox RJ, Salter A. Shared decision making and autonomy among US participants with multiple sclerosis in the NARCOMS registry. Int J MS Care. 2017;19(6):303–312. doi:10.7224/1537-2073.2016-091
   PubMedGoogle Scholar
• Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - A means to understand. Curr Med Res Opin. 2008;24(11):3063–3072. doi:10.1185/03007990802457040
   PubMed Web of Science ®Google Scholar
• Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352. doi:10.1136/bmjopen-2015-010352
   PubMed Web of Science ®Google Scholar
• Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–380. doi:10.2147/dmso.S120101
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452. doi:10.1212/wnl.33.11.1444
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. Appl Health Econ Health Policy. 2017;15(2):127–137. doi:10.1007/s40258-017-0310-5
   PubMed Web of Science ®Google Scholar
• McGuigan C, Hutchinson M. The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure. J Neurol Neurosurg Psychiatry. 2004;75(2):266–269.
   PubMed Web of Science ®Google Scholar
• Phillips GA, Wyrwich KW, Guo S, et al. Responder definition of the multiple sclerosis impact scale physical impact subscale for patients with physical worsening. Mult Scler. 2014;20(13):1753–1760. doi:10.1177/1352458514530489
   PubMed Web of Science ®Google Scholar
• Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research. Blackwell Science Ltd; 2002.
   Google Scholar
• Franchetti Y. Use of propensity scoring and its application to real world data: advantages, disadvantages, and methodological objectives explained to researchers without using mathematical equations. J Clin Pharmacol. 2021. doi:10.1002/jcph.1989
   Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679. doi:10.1002/sim.6607
   PubMed Web of Science ®Google Scholar
• Allan V, Ramagopalan SV, Mardekian J, et al. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J Comp Eff Res. 2020;9(9):603–614. doi:10.2217/cer-2020-0013
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• StataCorp LLC. Stata Statistical Software: Release 17. StataCorp LLC; 2021.
   Google Scholar
• EphRMA. European Pharmaceutical Market Research Association (EphMRA) code of conduct 2019; 2019. Available from: http://www.ephmra.org/Code-of-Conduct-Support. Accessed November 22, 2019.
   Google Scholar
• Rosenbloom ST, Smith JRL, Bowen R, Burns J, Riplinger L, Payne TH. Updating HIPAA for the electronic medical record era. J Am Med Inform Assoc. 2019;26(10):1115–1119. doi:10.1093/jamia/ocz090
   PubMed Web of Science ®Google Scholar
• Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med Decis Making. 2015;35(1):114–131. doi:10.1177/0272989x14551638
   PubMed Web of Science ®Google Scholar
• Ben-Zacharia A, Adamson M, Boyd A, et al. Impact of shared decision making on disease-modifying drug adherence in multiple sclerosis. Int J MS Care. 2018;20(6):287–297. doi:10.7224/1537-2073.2017-070
   PubMedGoogle Scholar
• Koudriavtseva T, Onesti E, Pestalozza IF, Sperduti I, Jandolo B. The importance of physician-patient relationship for improvement of adherence to long-term therapy: data of survey in a cohort of multiple sclerosis patients with mild and moderate disability. Neurol Sci. 2012;33(3):575–584. doi:10.1007/s10072-011-0776-0
   PubMed Web of Science ®Google Scholar
• Hawkes N. Seeing things from the patients’ view: what will it take? BMJ. 2015;350:g7757. doi:10.1136/bmj.g7757
   Google Scholar
• Jonker MF, Donkers B, Goossens LMA, et al. Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options. Med Decis Making. 2020;40(2):198–211. doi:10.1177/0272989x19897944
   PubMed Web of Science ®Google Scholar
• DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298–1304. doi:10.7326/m22-1460
   PubMed Web of Science ®Google Scholar